Message from the CEO
Board of Directors
Scientific Advisors
Hanns Pielenz
In Memoriam
Hanns A. Pielenz
Former President of Fibrotec Ventures, LLC
At Promedior, we continue to be inspired by and grateful to Hanns A. Pielenz, founder and former President of Fibrotec Ventures, LLC who served on Promedior's Board of Directors from 2012 until his death in 2013. In his time on Promedior's Board, his wisdom and thoughtfulness helped to guide and shape the company's plans and strategy.

When he was diagnosed with myelofibrosis in 2011, Hanns decided that his legacy would be to develop, fund, and coordinate medical, financial, and visionary business resources to find a cure for this serious, life-limiting disease. It was as part of this tireless quest that Hanns committed his company to a significant investment in Promedior and joined its Board.

We at Promedior are committed to our drug development programs in myleofibrosis and other serious fibrotic diseases, striving to ensure that Hanns' legacy will help advance potential treatments for patients in need.

Board of Directors

Jim was a co-founder and serves as Chairman at Promedior. Jim is a co-founder and Chairman at Ra Pharmaceuticals, a biotech company developing a new class of drugs with the diversity and specificity of antibodies, coupled with the bioavailability of small molecules. Jim was the founding CEO and currently serves as a Board member at SetPoint Medical, a company developing implantable neurostimulation devices to treat inflammatory diseases such as Crohn's Disease and Rheumatoid Arthritis as an alternative to drug therapy. He is an investor and board member of several other novel biotech and medical device companies, including OncoMed Pharmaceuticals, the leader in the field of drugs targeting cancer cell pathways, and Spine Wave, a commercial stage company selling multiple innovative devices for spinal surgery. Jim is a graduate of MIT (Bachelors in Mechanical Engineering) and University of Massachusetts (Doctor of Medicine).

Dr. Bruhn joined Promedior in May 2012 from Shire plc, where she was the Senior Vice President of Strategic Planning and Program Management in the Human Genetic Therapies business. While at Shire and Transkaryotic Therapies (acquired by Shire in 2005), she was responsible for the development of multiple protein therapeutics with annual sales today of over $1 billion. During her 13 year tenure she held significant roles driving strategy, portfolio management, program management, and global regulatory affairs for the rare disease portfolio. Prior to that she was at Cytotherapeutics, Inc., with a key role developing the encapsulated cell technology platform for ophthalmic delivery. Dr. Bruhn is a member of the Board of Directors of Raptor Pharmaceuticals, a public company focusing on treatments for orphan diseases, and the Crittenton Women's Union. She has a Ph.D. from MIT and a B.S. from Iowa State University.

Amir Nashat, Ph.D., is a General Partner in the Boston office of Polaris Venture Partners. Prior to joining Polaris, Dr. Nashat completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. His doctoral research focused on information flow through neurons, neural implants, and neural tissue engineering. Dr. Nashat currently represents Polaris as a Director of aTyr Pharmaceuticals, BIND Biosciences, Fate Therapeutics, Living Proof, Pervasis Therapeutics, Promedior Pharmaceuticals and Selecta Biosciences. Amir played an instrumental role in the inception of Living Proof, Pervasis and Sun Catalytix Corporation, serving as the founding President of all three companies. Additionally, Amir has served as a Director of Avila Therapeutics (acquired by Celgene), Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), and Hydra Biosciences, and as an Observer of GI Dynamics and Advion.

Prior to obtaining his Ph.D. at MIT, Dr. Nashat earned both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Gus Lawlor has been a managing director of HealthCare Ventures (HCV) since 2000. Mr. Lawlor has over 15 years of experience in the biotechnology industry in finance, business development, mergers and acquisitions, and general management. Prior to joining HCV in 2000, he was previously chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company, which was aquired by Millennium Pharmaceuticals. Before joining LeukoSite, he was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. He was previously a management consultant with KPMG Peat Marwick. Mr. Lawlor is a member of the board of directors of the Slater Center in Providence, Rhode Island. He received a Master's degree in Public and Private Management from Yale University.

Geert-Jan Mulder, M.D., co-founded Forbion in 2006 and currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA® (dalfampridine) board panel to evaluate a new clinical endpoint in Multiple Sclerosis; PanGenetics B.V. which sold to Abbott, where he led the Series B financing round; and Transave, where supported the company’s clinical development for ARIKAYCE® (liposomal amikacin for inhalation) partly as interim CMO, he also served on the Board of Directors till the merger with Insmed (NASDAQ:INSM) in 2010.

Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan received his Medical Degree from the University of Utrecht (NL) and spent two years as a clinician in Obstetrics and Gynecology at the University Medical Center of Utrecht (UMC). He then joined Searle (now Pfizer) working in the field of Arthritis & Pain, involved in clinical development as well as in the European Advocacy Development for the pre-launch of Celebrex®. After transitioning to Byk Gulden (now Takeda) he became Clinical Research Manager, where his department was responsible for the design and execution of numerous early and late stage clinical trials that formed the basis for two global product registrations, i.e. Daxas® and Alvesco® in the field of Respiratory Medicine (asthma and COPD). He was a member of the Global Medical Marketing group of their Respiratory Franchise and was involved in the line extension program for Pantozol®.

John H. Friedman is the Founding and Managing Partner of Easton Capital Group. Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, Mr. Friedman was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. During his tenure, Mr. Friedman was involved in Warburg's investments in Computerland, Tweeds, Babbages' and US Healthcare. Previously, John was an attorney with Sullivan and Cromwell. He holds a JD degree from Yale Law School and a BA degree, magna cum laude and Phi Beta Kappa, from Yale College. Mr. Friedman currently serves on the Boards of Promedior, Experimed, Trellis Bioscience, Cardiovascular Systems, Xoft, iTherX, PlaySpan. He was also co-chairman of the President's Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art and the Neighborhood Coalition for Shelter.

Nancy is the Chief Financial Officer of HAP Investment Group, LLC, the family office for the Hanns A. Pielenz family. In this role, she is active in sourcing, negotiating, and managing entrepreneurial investments in real estate, venture capital, and operating entities in diverse industries. Her background is in banking and finance, and she was a partner in First Union's Private Capital Management Group prior to the formation of HAP Investment Group in 2000. Nancy sits on the Board of Directors of Parata Systems, a Durham, North Carolina pharmaceutical technology company; Magnolia Bluffs Casino, a Natchez, Mississippi gaming facility; and Urban Expositions, an Atlanta-based trade show management company. She is also a member of the Board of Trustees of St. Mary's School in Raleigh, North Carolina. She has a B.S. and an M.B.A. from the University of North Carolina.

An accomplished entrepreneur in the life sciences industry, Mr. Weisman is currently President and Chief Executive Officer at Seventh Sense Biosystems. Prior to joining Seventh Sense, he was the founder, Chairman and Chief Executive Officer of EKR Therapeutics, a specialty pharmaceutical company focused in the hospital critical care market. Mr. Weisman was also co-founder of ESP Pharma where he served as a director in addition to the company's President and Chief Operating Officer until its sale to PDL Biopharma in 2005. He began his career in sales and marketing at Merck and Co., Inc. and later moved to Parke-Davis where he launched that company's diabetes franchise in 1997. Mr. Weisman graduated with a BA in Chemistry from Rutgers University.


Promedior's mission is to develop and advance targeted therapeutics to address the significant unmet needs of patients with diseases involving fibrosis. Learn More >